Detail akcie NovAccess Global Rg online

Business Summary: NovAccess Global Inc. is a biopharmaceutical company. The Company develops immunotherapies to treat brain tumor patients in the United States. It specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.
Financial Summary: BRIEF: For the fiscal year ended 30 September 2024, NovAccess Global Inc revenues was not reported. Net loss applicable to common stockholders decreased 44% to $2.7M. Lower net loss reflects Selling, general and administrative decrease of 68% to $748K (expense), Loss on derivatives decrease of 91% to $112K (expense), Interest Expense decrease of 48% to $635K (expense).